CN108079312A - 用于肟键联的亲核性催化剂 - Google Patents

用于肟键联的亲核性催化剂 Download PDF

Info

Publication number
CN108079312A
CN108079312A CN201810090885.7A CN201810090885A CN108079312A CN 108079312 A CN108079312 A CN 108079312A CN 201810090885 A CN201810090885 A CN 201810090885A CN 108079312 A CN108079312 A CN 108079312A
Authority
CN
China
Prior art keywords
growth factor
factor
protein
soluble polymer
bmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810090885.7A
Other languages
English (en)
Chinese (zh)
Inventor
J·西克曼
S·海德尔
H·罗滕施泰纳
A·伊文思
P·图雷切克
O·卓耶奇林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Hundred Deep Co
Hundred Deep LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hundred Deep Co, Hundred Deep LLC filed Critical Hundred Deep Co
Publication of CN108079312A publication Critical patent/CN108079312A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201810090885.7A 2010-07-30 2011-07-29 用于肟键联的亲核性催化剂 Pending CN108079312A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36918610P 2010-07-30 2010-07-30
US61/369,186 2010-07-30
CN2011800476351A CN103370082A (zh) 2010-07-30 2011-07-29 用于肟键联的亲核性催化剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2011800476351A Division CN103370082A (zh) 2010-07-30 2011-07-29 用于肟键联的亲核性催化剂

Publications (1)

Publication Number Publication Date
CN108079312A true CN108079312A (zh) 2018-05-29

Family

ID=44629987

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810090885.7A Pending CN108079312A (zh) 2010-07-30 2011-07-29 用于肟键联的亲核性催化剂
CN2011800476351A Pending CN103370082A (zh) 2010-07-30 2011-07-29 用于肟键联的亲核性催化剂
CN201810089901.0A Pending CN108079311A (zh) 2010-07-30 2011-07-29 用于肟键联的亲核性催化剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN2011800476351A Pending CN103370082A (zh) 2010-07-30 2011-07-29 用于肟键联的亲核性催化剂
CN201810089901.0A Pending CN108079311A (zh) 2010-07-30 2011-07-29 用于肟键联的亲核性催化剂

Country Status (26)

Country Link
EP (3) EP2598172B1 (cg-RX-API-DMAC7.html)
JP (7) JP6325818B2 (cg-RX-API-DMAC7.html)
KR (6) KR102229967B1 (cg-RX-API-DMAC7.html)
CN (3) CN108079312A (cg-RX-API-DMAC7.html)
AR (1) AR082941A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011282571C1 (cg-RX-API-DMAC7.html)
BR (1) BR112013001611B1 (cg-RX-API-DMAC7.html)
CA (1) CA2806684C (cg-RX-API-DMAC7.html)
CY (1) CY1121943T1 (cg-RX-API-DMAC7.html)
DK (1) DK2598172T3 (cg-RX-API-DMAC7.html)
EA (2) EA025738B9 (cg-RX-API-DMAC7.html)
ES (1) ES2731626T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190990T1 (cg-RX-API-DMAC7.html)
HU (1) HUE043790T2 (cg-RX-API-DMAC7.html)
LT (1) LT2598172T (cg-RX-API-DMAC7.html)
MX (1) MX346271B (cg-RX-API-DMAC7.html)
NZ (1) NZ605972A (cg-RX-API-DMAC7.html)
PL (1) PL2598172T3 (cg-RX-API-DMAC7.html)
PT (1) PT2598172T (cg-RX-API-DMAC7.html)
RS (1) RS58900B1 (cg-RX-API-DMAC7.html)
SG (2) SG187171A1 (cg-RX-API-DMAC7.html)
SI (1) SI2598172T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900351T1 (cg-RX-API-DMAC7.html)
TR (1) TR201908836T4 (cg-RX-API-DMAC7.html)
TW (1) TWI534152B (cg-RX-API-DMAC7.html)
WO (1) WO2012016131A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
TWI534152B (zh) * 2010-07-30 2016-05-21 巴克斯特國際公司 用於肟連接的親核性催化劑
ES2800983T3 (es) 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
HK1200695A1 (en) * 2012-04-16 2015-08-14 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
WO2017062832A1 (en) 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
TW201731869A (zh) * 2015-12-03 2017-09-16 百克莎塔股份有限公司 具有延長之半衰期及降低之配位體結合性質的因子viii
WO2018017923A1 (en) * 2016-07-22 2018-01-25 Nektar Therapeutics Conjugates of a factor viii moiety having an oxime-containing linkage
KR20250057110A (ko) 2017-05-15 2025-04-28 넥타르 테라퓨틱스 지속 작용성 인터류킨-15 수용체 효현제 및 관련 면역요법 조성물 및 방법
CA3126476A1 (en) 2019-01-23 2020-07-30 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
WO2022182768A1 (en) 2021-02-26 2022-09-01 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
WO2025133203A1 (en) * 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Compounds and methods for a long-lasting pam

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
CN101535339A (zh) * 2006-09-01 2009-09-16 诺沃-诺迪斯克保健股份有限公司 改性糖蛋白

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113492A (en) 1978-02-24 1979-09-05 Sanyo Chem Ind Ltd Preparation of glucoprotein derivative
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
ATE198277T1 (de) 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5574187A (en) * 1994-10-06 1996-11-12 Uniroyal Chemical Company, Inc. Process of preparing para substituted phenylamines
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
AU2001258536A1 (en) 2000-05-16 2001-11-26 Lipoxen Technologies Limited Derivatisation of proteins in aqueous solution
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
MXPA05002594A (es) 2002-09-11 2005-05-27 Fresenius Kabi Gmbh Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
WO2004089280A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
TWI356065B (en) * 2003-08-08 2012-01-11 Fresenius Kabi De Gmbh Method of producing hydroxyalkyl starch derivative
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
WO2005014024A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of a polymer and a protein linked by an oxime linking group
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
ES2422187T3 (es) 2003-12-03 2013-09-09 Biogenerix Ag Factor estimulante de colonias de granulocitos glicopegilados
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP1776389B1 (en) 2004-08-12 2016-06-29 Lipoxen Technologies Limited Sialic acid derivatives
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
AU2005322067B8 (en) 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
CA2611823C (en) 2005-06-16 2013-07-30 Nektar Therapeutics Al, Corporation Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US20100056428A1 (en) * 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
EP2201953A4 (en) * 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp USE OF RIBAVIRIN IN BLOOD CLEANING DISORDERS
GB0908393D0 (en) * 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method
EP3081233B1 (en) * 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
BR112012001814A8 (pt) * 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
EA201290069A1 (ru) * 2009-07-31 2012-07-30 Байер Хелскер Ллс Модифицированные полипептиды фактора ix и их применения
TWI534152B (zh) * 2010-07-30 2016-05-21 巴克斯特國際公司 用於肟連接的親核性催化劑

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
CN101535339A (zh) * 2006-09-01 2009-09-16 诺沃-诺迪斯克保健股份有限公司 改性糖蛋白

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANOUK DIRKSEN ET AL.: "Nucleophilic Catalysis of Oxime Ligation", 《ANGEWANDTE CHEMIE INTERNATIONAL EDITION》 *
MIKKEL B. THYGESEN, ET AL.: "Nucleophilic Catalysis of Carbohydrate Oxime Formation by anilines", 《THE JOURNAL OF ORGANIC CHEMISTRY》 *

Also Published As

Publication number Publication date
SMT201900351T1 (it) 2019-07-11
NZ605972A (en) 2015-04-24
SI2598172T1 (sl) 2019-08-30
AR082941A1 (es) 2013-01-23
JP2021038256A (ja) 2021-03-11
HRP20190990T1 (hr) 2019-10-04
CY1121943T1 (el) 2020-10-14
JP2015164958A (ja) 2015-09-17
JP7258999B2 (ja) 2023-04-17
EP3505186A1 (en) 2019-07-03
KR20200126008A (ko) 2020-11-05
AU2011282571B2 (en) 2015-09-24
JP6325818B2 (ja) 2018-05-16
ES2731626T3 (es) 2019-11-18
RS58900B1 (sr) 2019-08-30
KR20210032542A (ko) 2021-03-24
PT2598172T (pt) 2019-06-25
JP2017137358A (ja) 2017-08-10
EP3505186B1 (en) 2022-01-12
BR112013001611A8 (pt) 2020-10-27
AU2011282571C1 (en) 2018-04-05
WO2012016131A1 (en) 2012-02-02
AU2011282571A1 (en) 2013-02-07
JP2019116500A (ja) 2019-07-18
BR112013001611B1 (pt) 2022-05-10
KR102088852B1 (ko) 2020-03-16
BR112013001611A2 (pt) 2016-05-17
JP2013536180A (ja) 2013-09-19
MX346271B (es) 2016-07-08
SG187171A1 (en) 2013-02-28
KR20210079392A (ko) 2021-06-29
KR102172133B1 (ko) 2020-11-02
LT2598172T (lt) 2019-08-26
EA025738B1 (ru) 2017-01-30
KR101969601B1 (ko) 2019-04-17
PL2598172T3 (pl) 2019-09-30
KR20190040364A (ko) 2019-04-17
KR20200029059A (ko) 2020-03-17
EP4023247A1 (en) 2022-07-06
CA2806684A1 (en) 2012-02-02
TWI534152B (zh) 2016-05-21
DK2598172T3 (da) 2019-07-01
CN108079311A (zh) 2018-05-29
JP2019116501A (ja) 2019-07-18
EP2598172B1 (en) 2019-03-27
TW201217393A (en) 2012-05-01
KR102229967B1 (ko) 2021-03-19
KR102269494B1 (ko) 2021-06-25
EA201691292A1 (ru) 2017-08-31
EA201300190A1 (ru) 2013-07-30
JP6757823B2 (ja) 2020-09-23
CA2806684C (en) 2020-11-17
JP7054407B2 (ja) 2022-04-13
MX2013001261A (es) 2013-03-22
EP2598172A1 (en) 2013-06-05
SG10201913078SA (en) 2020-02-27
KR20130043211A (ko) 2013-04-29
HUE043790T2 (hu) 2019-09-30
EA025738B9 (ru) 2018-05-31
JP2022046676A (ja) 2022-03-23
TR201908836T4 (tr) 2019-07-22
CN103370082A (zh) 2013-10-23
KR102325780B1 (ko) 2021-11-12

Similar Documents

Publication Publication Date Title
JP7258999B2 (ja) オキシム連結のための求核触媒
JP7304402B2 (ja) オキシム連結のための求核触媒
AU2017276255A1 (en) Nucleophilic Catalysts for Oxime Linkage

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Zug City

Applicant after: Hundred deep limited liability company

Applicant after: Hundred deep company

Address before: Aupu, Switzerland

Applicant before: Hundred deep limited liability company

Applicant before: Hundred deep company

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210706

Address after: Osaka

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Zug City

Applicant before: BAXALTA GmbH

Applicant before: Baishen Co.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180529